about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewPregnancy and virologic response to antiretroviral therapy in South AfricaImplications of gender and pregnancy for antiretroviral drug dosingKinetics and determining factors of the virologic response to antiretrovirals during pregnancy.Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.Lopinavir protein binding in HIV-1-infected pregnant women.Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.Antiretroviral regimens in pregnancy and breast-feeding in Botswana.Raltegravir pharmacokinetics during pregnancy.Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Highlights from the United States Food and Drug Administration's public workshop on the development of animal models of pregnancy to address medical countermeasures in an "at-risk" population of pregnant women: Influenza as a case study.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancyAlteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.Atazanavir pharmacokinetics with and without tenofovir during pregnancyImmune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.Clinical therapeutics in pregnancy.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.Effect of pregnancy on emtricitabine pharmacokinetics.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavirModel-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy
P2860
Q28109657-A046A0AD-1426-4E72-AEFF-3E9F44AED316Q28741879-3903B962-455F-4927-BB62-56286480724AQ33584069-F7450A91-69D4-418D-AE9D-AA160140F9C2Q33622168-94902D0E-9FBD-4AEE-B05E-3F7A44F7B4ABQ33749434-9138C181-41F9-4AF2-BB7E-7E730BB959B1Q33811876-3B6693E8-2DAA-4738-8B69-ED5CD4A68CECQ33869395-2098FD22-5CA3-4C5C-918E-65C04C376DA0Q33887266-92BFC9C2-51CC-45D8-A9FB-D5E13DC5A2B4Q33962762-55691195-70A5-402A-ADEF-25687DFCBF1FQ33968260-FD5DA961-E545-4278-8F8F-062AAAA86209Q34057304-D22380EA-6F32-4BFE-9C04-2E04BCD37EC4Q34395082-0ADDE098-5AA9-4266-8C07-F2DB5EBCF0A5Q34422111-0F16BCF3-DE94-4825-9C41-775AFF19F161Q34429204-0E4A4BEE-7593-43A8-9F3C-9E6038824D62Q34442499-75FD283D-E168-484E-B167-1844B5C86DE9Q34483505-F9EE2C89-796F-4080-884E-E3C729173264Q34511184-8822C849-408A-4401-95A4-162682D0B51CQ34710705-BC1A116C-7578-498A-B3EA-6974B5B99BE8Q34758192-A1C61517-03C3-40D0-900A-DC381C3A36EBQ35060812-F1AD30BE-D77E-458D-BDBB-8F110FEF26E1Q35074548-02409F79-59AA-46D7-9D2D-67A3A65A3B66Q35082567-AF2BA9C4-05ED-4562-A389-EB9AE7C8B298Q35113890-7AF58C31-AE8A-4FBD-8300-78D348EAA584Q35557216-8E33428C-12FF-4644-A159-A52DC414DF2BQ35597592-40056A36-7EDC-47C8-A4EE-671000C05B9BQ35627832-8C91A05B-0A63-4C45-B923-E441AD42FF60Q35689226-EAA7A3F3-8E1E-494D-96F8-8489B205C8BCQ35691909-1D9A5D95-465D-4FC0-8C48-536E4EBE7FCBQ35784583-D258DD3E-5404-44CB-88B9-D7C903B95A6BQ35930696-5401035D-0EE3-45FA-966A-1BC07AF6C92EQ35960706-AAE9128F-8B45-4070-BBCE-CA8B66B8D3AFQ36084313-68889A0C-F191-4F3E-91A3-9A58F9775458Q36187641-D875FEBB-9813-4E45-B317-698C53D9CDF4Q36193307-BFA3FAF6-D867-41AC-8609-AD4E7A32CF8AQ36439051-160B8B12-4DFF-4CE0-B552-24FC73DD3B80Q36644765-379EC7BE-647D-495A-B0D6-B7765BC43F3DQ36676527-0A3EBF62-DB80-4F99-8109-59B78CEDB9B4Q36676538-C027F4EE-B670-461E-95AA-5DCF1DF33923Q36727919-491655F3-4F1A-43FA-AD9D-8721A2B19800Q36763067-AED49DC3-C5F3-41CB-A6BA-5F63BF83CE70
P2860
description
2006 nî lūn-bûn
@nan
2006 թվականի հոկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Reduced lopinavir exposure during pregnancy.
@en
Reduced lopinavir exposure during pregnancy.
@nl
type
label
Reduced lopinavir exposure during pregnancy.
@en
Reduced lopinavir exposure during pregnancy.
@nl
prefLabel
Reduced lopinavir exposure during pregnancy.
@en
Reduced lopinavir exposure during pregnancy.
@nl
P2093
P1433
P1476
Reduced lopinavir exposure during pregnancy.
@en
P2093
Alice M Stek
Amanda Cotter
Brookie M Best
Carol Elgie
Chengcheng Hu
Diane T Holland
Edmund Capparelli
Jennifer S Read
Mark Mirochnick
Ruth Tuomala
P304
P356
10.1097/01.AIDS.0000247114.43714.90
P407
P577
2006-10-01T00:00:00Z